Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Els M E, Verdegaal"'
Autor:
Diane van der Woude, Theo Rispens, Catharina M Korse, Sjoerd H van der Burg, Ellen Kapiteijn, John B A G Haanen, Winan J van Houdt, Els M E Verdegaal, Marij J P Welters, Jessica S W Borgers, Tineke J van Wesemael, Johannes V van Thienen, Kyra A Gelderman, Dirk J A R Moes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Introduction Treatment with the immune checkpoint inhibitor anti-programmed cell death protein-1 (PD-1) often causes immune-related adverse events (irAEs). Since irAEs resemble autoimmune diseases, autoantibodies might play a role and could potential
Externí odkaz:
https://doaj.org/article/9616b7f6fe8b499baab93acfee17c709
Autor:
Judith R Kroep, Sjoerd H van der Burg, Marten Visser, Linda de Bruin, Pauline Meij, Inge Roozen, Els M E Verdegaal, Caroline E van der Minne, Marij J P Welters, Saskia J Santegoets, Nikki M Loof, Sanne Boekestijn, Pita M de Kok, Inge M Westra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background The presence of T cells and suppressive myeloid cells in epithelial ovarian cancer (EOC) correlate with good and bad clinical outcome, respectively. This suggests that EOC may be sensitive to adoptive cell therapy with autologous tumor-inf
Externí odkaz:
https://doaj.org/article/23ac6018768843a28d87a7fb513a2cca
Autor:
Rosa A. van Amerongen, Sander Tuit, Anne K. Wouters, Marian van de Meent, Sterre L. Siekman, Miranda H. Meeuwsen, Tassilo L. A. Wachsmann, Dennis F. G. Remst, Renate S. Hagedoorn, Dirk M. van der Steen, Arnoud H. de Ru, Els M. E. Verdegaal, Peter A. van Veelen, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ova
Externí odkaz:
https://doaj.org/article/97169a79cc174ce282d2474ef1bf87ec
Autor:
Sjoerd H van der Burg, Rebekka Duhen, Thomas Duhen, Marieke E Ijsselsteijn, Ruud van der Breggen, Koen C M J Peeters, Noel F C C de Miranda, Els M E Verdegaal, Dina Ruano, Manon van der Ploeg, Jitske van den Bulk, Arantza Fariña-Sarasqueta
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background Expression of CD103 and CD39 has been found to pinpoint tumor-reactive CD8+ T cells in a variety of solid cancers. We aimed to investigate whether these markers specifically identify neoantigen-specific T cells in colorectal cancers (CRCs)
Externí odkaz:
https://doaj.org/article/a80924796f3f43ca978f61b4c5f9bebf
Autor:
Jitske van den Bulk, Els M. E. Verdegaal, Dina Ruano, Marieke E. Ijsselsteijn, Marten Visser, Ruud van der Breggen, Thomas Duhen, Manon van der Ploeg, Natasja L. de Vries, Jan Oosting, Koen C. M. J. Peeters, Andrew D. Weinberg, Arantza Farina-Sarasqueta, Sjoerd H. van der Burg, Noel F. C. C. de Miranda
Publikováno v:
Genome Medicine, Vol 11, Iss 1, Pp 1-15 (2019)
Abstract Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does
Externí odkaz:
https://doaj.org/article/1053242894a246058058f9231a19524f
Autor:
Gerrit-Jan Liefers, Sjoerd H van der Burg, Monique K van der Kooij, Marten Visser, Linda de Bruin, Ellen Kapiteijn, Els M E Verdegaal, Caroline E van der Minne, Pauline M Meij, Inge C F M Roozen, Mare A Jonker, Shelley van den Bosch, Frank M Speetjens
Publikováno v:
BMJ Open, Vol 10, Iss 11 (2020)
Introduction Treatment with anti-PD-1 immunotherapy does not lead to long-lasting clinical responses in approximately 60% of patients with metastatic melanoma. These refractory patients, however, can still respond to treatment with tumour infiltratin
Externí odkaz:
https://doaj.org/article/7801791fed264d05be8148157a140694
Autor:
Joachim G J V Aerts, Ron H J Mathijssen, Sjoerd H van der Burg, Reinhard Dummer, Reno Debets, Mandy van Brakel, Ellen Kapiteijn, Daan P Hurkmans, Els M E Verdegaal, Sabrina A Hogan, Rik de Wijn, Lies Hovestad, Dianne M A van den Heuvel, Rob Ruijtenbeek, Marij J P Welters, Edwin A Basak, Herbert M Pinedo, Cor H J Lamers, Harmen J G van de Werken, John P Groten, Mitchell P Levesque
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Many cancer patients do not obtain clinical benefit from immune checkpoint inhibition. Checkpoint blockade targets T cells, suggesting that tyrosine kinase activity profiling of baseline peripheral blood mononuclear cells may predict clini
Externí odkaz:
https://doaj.org/article/fdec7b4cc229438683584ce62dfcc0e3
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Somatic non-synonymous mutations in the DNA of tumor cells may result in the presentation of tumor-specific peptides to T cells. The recognition of these so-called neoepitopes now has been firmly linked to the clinical success of checkpoint blockade
Externí odkaz:
https://doaj.org/article/48518c0b0a3b4c0db2b1b184f7c32aec
Autor:
Jitske van den Bulk, Manon van der Ploeg, Marieke E Ijsselsteijn, Dina Ruano, Ruud van der Breggen, Rebekka Duhen, Koen C M J Peeters, Arantza Fariña-Sarasqueta, Els M E Verdegaal, Sjoerd H van der Burg, Thomas Duhen, Noel F C C de Miranda
Publikováno v:
Journal for immunotherapy of cancer, 11(2). BioMed Central Ltd.
BackgroundExpression of CD103 and CD39 has been found to pinpoint tumor-reactive CD8+T cells in a variety of solid cancers. We aimed to investigate whether these markers specifically identify neoantigen-specific T cells in colorectal cancers (CRCs) w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e07fae3acb459c146dbd06750ee1c162
https://doi.org/10.1136/jitc-2022-005887
https://doi.org/10.1136/jitc-2022-005887
Autor:
Marieke E. Ijsselsteijn, Els M. E. Verdegaal, Noel F C C de Miranda, Arantza Farina-Sarasqueta, Ruud van der Breggen, Dina Ruano, Andrew D. Weinberg, Natasja L. de Vries, Jitske van den Bulk, Sjoerd H. van der Burg, Jan Oosting, Koen C. M. J. Peeters, Marten Visser, Thomas Duhen, Manon van der Ploeg
Publikováno v:
Genome Medicine, Vol 11, Iss 1, Pp 1-15 (2019)
Genome Medicine
Genome Medicine
Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not excl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eb0f7346c75698ef9e1cb8c49865ae4
https://doaj.org/article/1053242894a246058058f9231a19524f
https://doaj.org/article/1053242894a246058058f9231a19524f